Interviews

ADCs and oral SERDs are reshaping breast cancer care, easing toxicity but adding new sequencing, HER2 testing, and adherence challenges.

Lidia Schapira, MD, Stanford, urges care teams to weigh quality of life, not just scans, in long-term cancer therapy decisions.

Bridget Keenan, MD, PhD, of UCSF, stresses close communication across clinical, industry, and lab teams to run safe CAR T-cell trials.

CAR T remains Madhav Seshadri, MD's top pick for eligible relapsed/refractory DLBCL, though bispecific antibody regimens are viable alternatives.

Peter Forsberg, MD, discusses why health systems must adapt to expand equitable access to CAR T-cell and bispecific therapies.

Multidisciplinary geriatric oncology helps personalize breast cancer care and preserve quality of life for older adults.

Hans Lee, MD, lays out the tradeoffs in travel, time off therapy, and who each option realistically fits when looking at CAR T-cell and bispecific therapies.

Anosheh Afghahi, MD, explains how integrated health technologies can improve clinical trial matching, efficiency, and equity.

Enrique Soto Perez de Celis, MD, PhD, discusses designing breast cancer trials around outcomes older adults value, including independence and quality of life.

Integrated specialty pharmacies have EHR access, faster prior authorizations, and built-in monitoring, Brooke Looney, PharmD, CSP, highlighted.

Anosheh Afghahi, MD, discusses biomarker testing, trial matching technology, and community-academic partnerships to improve enrollment.

Benjamin Garmezy, MD, explains what varying Nectin-4 expression means for treatment selection in bladder cancer and what trials are still needed.

Urs Weber, MD, explains how multidisciplinary teams streamline biomarker testing and improve treatment planning in thoracic oncology.

Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal.

Urs Weber, MD, discusses why comprehensive NGS is critical and where community biomarker testing often falls short.

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used.

Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease.

Stefanie Houseknecht, PharmD, explains how oncology pharmacists support biomarker testing, targeted therapy selection, and patient education in lung cancer care.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer treatment and survivorship.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Robert Kratzke, MD, calls for a national biomarker testing mandate, emphasizing that timely genomic testing is essential for precision lung cancer care.

Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.

Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.